For someone living with advanced pancreatic cancer, time can take on a different meaning. A birthday, a family dinner, a trip that once seemed ordinary can become something worth fighting for. For 83-year-old Helene Rubin, that reality became personal after doctors discovered that her pancreatic cancer had spread to her lungs and told her to look for a clinical trial when standard treatment offered few remaining options.

She found one at Memorial Sloan Kettering in February 2026, where researchers were testing a pill called daraxonrasib. The treatment initially made her sick enough to require hospitalization, and she could have chosen to stop. Instead, Rubin decided to continue, hoping the drug might help her while also contributing to research that could benefit people facing the same diagnosis. Months later, her experience became part of a much larger story about what happens when researchers finally find a way to target one of cancer’s most difficult biological problems.

Pancreatic Cancer Has Long Been Difficult To Treat

Pancreatic cancer remains one of the most serious cancers in the United States, with about 67,000 people diagnosed each year. When the disease has already spread to other parts of the body, treatment becomes especially difficult, and survival rates remain poor. Between 2015 and 2021, roughly 97% of people diagnosed with metastatic pancreatic cancer died within five years, according to figures cited in the material surrounding the new treatment.

For many patients, chemotherapy has been the primary option. It can slow the disease, but the physical cost can be substantial. Rubin experienced that reality herself. “On chemo, I couldn’t get off the couch and I was always nauseous and lost a ton of weight,” she said.

That experience captures a difficult part of cancer treatment that statistics cannot fully describe. A treatment can extend survival while also affecting how a person spends those additional months. For patients and families, the question has increasingly become about both quantity and quality of life.

Researchers Found A Different Way Into The Cancer

Much of the difficulty surrounding pancreatic cancer comes from a mutation involving a gene called KRAS. More than 90% of pancreatic tumors carry KRAS mutations, and the protein produced by the gene plays a central role in controlling cell growth. When the gene mutates, that growth signal can become stuck in an active state, encouraging cancer cells to continue multiplying.

Scientists have known about KRAS for decades, but targeting the protein with conventional drugs proved exceptionally difficult. Its surface lacks the obvious molecular pockets that many medicines use to attach themselves to a protein. Researchers spent years searching for another way to interfere with the signal.

Daraxonrasib takes a different route. Rather than attempting to attach directly to KRAS, it binds with a molecule called cyclophilin A inside the cell. That combination creates a structure capable of interacting with active KRAS and blocking the growth signal. The approach opened a path into a problem that had resisted many previous attempts.

The science may sound highly technical, but the human meaning is easier to understand. Researchers were looking for a way to interfere with one of the mechanisms helping pancreatic cancer survive, while giving patients an option that could potentially be easier to tolerate than conventional chemotherapy.

The Trial Produced A Striking Difference

The treatment was studied in the RASolute 302 trial, which included 500 people with metastatic pancreatic adenocarcinoma who had already received at least one chemotherapy treatment. Participants were divided between daraxonrasib and the chemotherapy chosen by their doctors.

The difference in median survival was substantial. Patients receiving daraxonrasib lived a median of 13.2 months, compared with 6.7 months among those receiving chemotherapy. The trial also found a lower risk of death among people receiving the drug.

Tumor response showed a similar pattern. Around 30% of patients taking daraxonrasib experienced measurable tumor shrinkage, compared with 11% among those receiving chemotherapy. The disease also remained controlled for a median of 7.2 months with daraxonrasib, compared with 3.6 months with chemotherapy.

For oncologists who have spent years caring for people with advanced pancreatic cancer, numbers like these can carry an emotional weight that is difficult to capture in a clinical table. Brian Wolpin, who presented the findings at the American Society of Clinical Oncology annual meeting in Chicago, later said, “That time was not built into my talk,” referring to the standing ovation that followed the presentation.

More Time Can Mean More Than A Number

Survival is one way to measure a cancer treatment, but it does not describe everything a patient experiences. Researchers also looked at pain and found that patients receiving daraxonrasib went a median of 9.2 months before their pain worsened. For those receiving chemotherapy, the figure was 3.8 months.

That difference matters because additional time only feels like additional time when a person can use it. A patient who can sit at the dinner table, make plans with family, travel, work on a favorite project, or simply enjoy an ordinary morning may experience those months very differently from someone overwhelmed by treatment side effects.

Rubin’s own experience offers a glimpse of that distinction. After her dose was reduced, she said the lung nodules had shrunk and described the difference in side effects as “amazing.” She still experienced some side effects, but said they generally did not interfere with what she did or how she felt.

Mary Larsen, the clinical trials nurse who cared for Rubin, described the change in terms that reach beyond medical measurements: “They can live like a person and not just as a cancer patient.”

That sentence points to something often lost in discussions about cancer. Patients do not stop being parents, grandparents, partners, friends, workers, travelers, or individuals with plans simply because they receive a diagnosis. The best treatments give people space to remain those things.

The New Drug Still Comes With Serious Limits

Daraxonrasib is not a cure, and the results do not mean pancreatic cancer has suddenly become an easy disease to treat. More than 86% of patients in the trial developed a skin rash, while mouth sores, diarrhea, nausea, and vomiting were also reported. Some patients needed their dose reduced because of side effects.

The treatment also carries warnings involving serious complications, including gastrointestinal perforation and lung inflammation. Only a small percentage of patients stopped treatment because of side effects, but the risks remain an important part of understanding what the drug offers.

Cost presents another difficult question. A month’s supply has a listed price of $39,800 before insurance, putting access and affordability alongside medical effectiveness as major considerations for patients and healthcare systems.

There is also the fundamental uncertainty that accompanies advanced cancer. Cancer cells can adapt, and a treatment that works for one person may eventually become less effective. The approval therefore represents another option for a specific group of patients rather than a final answer to pancreatic cancer.

Helene Rubin Chose To Stay With The Trial

Rubin’s decision to remain in the clinical trial was personal, but it also reflects something larger about medical research. Every treatment that eventually becomes available to patients has passed through the experiences of people who were willing to participate in trials when the outcome was uncertain.

She had already experienced the exhaustion and nausea of chemotherapy. She then faced hospitalization after starting the experimental treatment. Walking away would have been understandable, yet she chose to continue.

“But I wanted to stick it out,” Rubin said, “both to see if the drug could help me and to contribute to helping other people with this disease.”

Her experience eventually became one example among hundreds in the clinical trial, but individual stories are where medical progress becomes tangible. A survival curve can show a difference between two groups. It cannot show what a grandmother does with an unexpected afternoon, what a family hears when she answers the phone, or how much an extra birthday can mean. Those moments are why survival statistics matter in the first place.

A Different Conversation In The Exam Room

The U.S. Food and Drug Administration approved daraxonrasib on August 26, 2026, under the brand name Rasonque for adults with metastatic pancreatic adenocarcinoma who have already received systemic therapy or cannot tolerate it. The approval arrived ahead of the agency’s original deadline.

The significance of the approval is therefore quite specific. It gives certain patients another treatment option after they have already faced chemotherapy, rather than replacing every existing approach to pancreatic cancer.

For doctors, however, an additional option can change the conversation with a patient. Peter Hosein, a medical oncologist with the Pancreatic Cancer Research Institute, described that shift simply: “Now with this treatment, they can start thinking about plans for the future, travel, family.”

That possibility is easy to overlook when medicine is discussed through survival statistics alone. A future plan may sound ordinary to someone who has never had that possibility taken away. For someone facing metastatic cancer, being able to make one can feel profound.

The Future Of Pancreatic Cancer Treatment Is Still Being Written

Eileen O’Reilly, the Memorial Sloan Kettering oncologist who worked on Rubin’s trial, has spent years treating pancreatic cancer. Reflecting on the results, she said, “To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease.” She also placed the development in perspective. “This drug is a sea change, but we are just at the beginning,” O’Reilly said.

That may be the most honest way to understand what has happened. Daraxonrasib does not erase the fear that comes with metastatic pancreatic cancer. It does not guarantee that every patient will respond, and it does not remove the physical or financial burdens that accompany treatment. What it can do is create more room for possibility.

For Helene Rubin, that possibility has already taken a concrete form. She stayed with the trial, her tumors responded, and she gained time that she can spend living rather than simply measuring how much time remains.

Thirteen months may look modest on paper. In a human life, it can contain an entire season of ordinary moments. And sometimes, those ordinary moments are precisely what people are fighting to keep.

Loading...